Therapeutics Development NOFOs
- RFA-OD-24-014: Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required)
- RFA-DA-25-028: Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional)
- PAR-24-064: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial optional)
- RFA-DA-25-058: Psychedelics Treatment Research in Substance Use Disorder (UG3/UH3)
- PAR-22-200: Development of medications to prevent and treat opioids/psychostimulant use disorders and overdose (UG3/UH3)
- PAR-22-202: Grand opportunity in medications development to treat substance use disorders (U01)
- PAR-22-182: Behavioral & integrative treatment development program (R01)
- PAR-22-183: Behavioral & integrative treatment development program (R34)
- PAR-21-183: Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3)
- PAR-20-279 Device-Based Treatments for Substance Use Disorders (UG3/UH3)
- PAR 20-030: HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)
- NOT-NS-20-005: Notice of Special Interest (NOSI): Research in the Emergency Setting
- NOT-DA-20-032: Notice of Special Interest (NOSI): The HIV-HCV-Substance Use Disorder Syndemic: Therapeutic Approaches
- NOT-DA-21-018: Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders
- PAS-21-270: AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)
- NOT-DA-21-017: Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19
- NOT-DA-21-19: Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders
- NOT-DA-21-011: Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection
- PA-21-205: Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)
- PAR 21-070: Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)
- RFA-DA-22-040: HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional)
- NOT-DA-23-041: Notice of Change to Application Due Date for RFA-DA-22-040, "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)"
- PAR-23-191: HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) (reissue)
- NOT-DA-24-002: Notice of Special Interest (NOSI): Chemsex and HIV: prevalence, medical/psychosocial consequences, and treatment
- NOT-DA-24-022: Notice of Change to Application Due Date for PAS-21-270, "AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)"
- NOT-DA-24-023: Notice of Change to Application Due Date for PA-21-205, "Development & Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)"
- NOT-DA-24-019: Notice of Pre-Application Technical Assistance Webinar for RFA-DA-25-060
- RFA-DA-25-040: High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
- RFA-DA-25-060: High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
- NOT-DA-24-030: Notice to Update PAR-23-194, "Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed)"
- NOT-DA-24-001: Notice of Special Interest (NOSI): Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine.
- NIDA Small Research Grant Program (R03 Clinical Trial Required)
- NOT-DA-21-080: Notice of Correction to the Key Date Section in PAR-21-320, "NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)"
- NOT-DA-22-055: Notice of Change to section for PAR-21-320, "NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)"
- NOT-DA-20-037: Notice of Special Interest (NOSI): Research Training and Career Development Awards to Support Individuals Pursuing Research Focused on Developing Treatments for Substance Use Disorders and the Associated Medical Consequences of these Disorders
- NOT-DA-20-013: Notice of Special Interest (NOSI): Drug-drug interactions among substances of abuse, medications to treat HIV infection, and pharmacotherapies to treat substance use disorders
- NOT-DA-18-008: Notice of expiration of PA-18-626 "NIDA Small Research Grant Program (R03 Clinical Trial Required)"
- PAR-22-058: Emergency Awards: HEAL Initiative: Translational Science Career Enhancement Awards for Early and Mid-career Investigators (K18 Clinical Trials Not Allowed)
- NOT-DA-24-12: Notice of Special Interest (NOSI): Xylazine: Understanding Its Use and the Consequences